Bing Yan News Today

Ming Yan, Chief Technology Officer of Cytek Biosciences Inc (NASDAQ:CTKB), sold 20,000 shares of the company on December 19, 2023, according to a recent SEC Filing.

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

The Center for Drug Evaluation of China’s National Medical Products Administration has accepted the new drug application seeking the approval of the next-generation ROS1 TKI taletrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer with prior exposure to a ROS1 TKI.

NEW YORK & SUZHOU, China--(BUSINESS WIRE)--Nov 22, 2023--

NEW YORK & SUZHOU, China--(BUSINESS WIRE)--Nov 22, 2023--

Vaccines are enhanced by adjuvants designed using computers. A Chinese research team has made a breakthrough in vaccine development by using computer-aided molecular design and machine learning to create two innovative adjuvants, which are substances added to vaccines to enhance the immune response

Many vaccines contain compounds known as adjuvants in addition to an antigen that stimulates the immune system. A Chinese research team has now created two nove

Heineken’s global CIO Ing Yan Ong plots a €10 billion digital business course consisting of AI, ERP consolidation, and predictive analytics to become the “best connected brewer.”

The evolving story of the historical Chinese drama “Ever Night: War of Brilliant Splendours,” airing weeknights at 10:15 PM on Kapamilya Channel, Jeepney TV, A2Z and TV5, promises more twists as it delves deeper into

In 67 ROS1 TKI-naïve patients, the confirmed objective response rate (cORR) and disease control rate (DCR) were 92.5% and 95.5%, respectively. In 38...